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Decades of experimental studies and clinical evidence depicted a scheme of atherogenesis that clearly highlights the involvement of all the cell types composing vessel walls, interacting with infiltrating inflammatory cells. Many other risks factors, like hypertension, diabetes, cholesterol levels and cigarette smoking, impact on atherogenesis, making things even more complex. On this notice, a variety of therapeutic and prevention strategies were able to reduce the risk deriving from the above mentioned factors, contributing to a significant part of the successes obtained in cardiovascular medicine.
The CANTOS trial 2 was conceived to test the hypothesis that inflammation and immune activation are pathogenetic events in the atherosclerotic disease and not simply bystander processes related to vascular tissue damage. Designed as a double-blinded randomized trial for secondary prevention of cardiovascular events, CANTOS enrolled 10 061 patients with prior myocardial infarction and elevated levels of high sensitivity Creactive protein (hsCRP), equal or higher than 2 mg/L. Randomized in four groups receiving canakinumab, a human monoclonal antibody neutralizing interleukin-1 b (IL-1b ), at three different dosages (50, 150 and 300 mg, administered subcutaneously every 3 months) or placebo, on top of their standard therapy. Accordingly to the trial's strategy, canakinumab significantly reduced hsCRP while leaving unaffected lipid levels. The primary endpoint of the study consisted in the first occurrence of major adverse cardiovascular events (MACE), as non-fatal myocardial infarction or stroke and cardiovascular death. The group receiving 150 mg of canakinumab showed 15% relative risk reduction, and no additional benefit was observed in the group receiving the higher dose. Conversely the lowest canakinumab dosage had no beneficial effect. When considering the key secondary endpoints, consisting in the primary ones plus hospitalization for unstable angina, the relative risk reduction obtained with 150 mg of canakinumab was even greater (17%). Neutropenia was the most serious adverse event observed, resulting in an increased risk of infections in patients treated with canakinumab (0.31% vs. 0.18% in the placebo group). However, considering the relatively rare incidence of these events, this result seems only suggestive that patients undergoing a potential treatment with canakinumab will require a strict monitoring for infections, as it is already recommended for subjects receiving other biologic anti-inflammatory therapies.
From biomarkers to molecular mechanisms relevant for therapeutic strategies
The concept of 'residual inflammatory risk' began to evolve when the investigators that later designed the CANTOS study, examined large sets of observations accumulated during the past decades, and showing that among patients with known cardiovascular disease and on high intensity statin treatment, there is a significant proportion of those who still have increased hsCRP. 3 From a clinical perspective, most of the evidence came from epidemiological studies showing a significant relationship between increased cardiovascular risk and the levels of circulating inflammatory biomarkers. Among these, hsCRP emerged as the most clinically relevant, as initially showed by the prospective Physicians Health Study (PHS) that in the end of 1990 s found stably elevated levels of hsCRP in patients at future risk for vascular events. 4 In 2010, the Emerging Risk Factor Consortium reviewed about 160 000 individuals, estimating three ranges of hsCRP levels connotating lower (hsCRP < 1 mg/L), intermediate (1-3 mg/L of hsCRP) or higher (hsCRP > 3 mg/L) relative risk. 5 Clinical data obtained by successive trials, like the REVERSAL, PROVE IT and IMPROVE-IT, corroborated this notion, extending the knowledge to the clinical concept of dual goals for statin therapy, with greatest clinical benefits observed in those who reduced LDL below 70 mg/dL and hsCRP below 2 mg/L. [6] [7] [8] In the end, with the outcome of JUPITER trial for primary prevention we also became aware that statin confers a further protection from first ever heart attack and stroke among those patients with low LDL levels but high hsCRP. 9 However, despite the reliability of clinical data supporting hsCRP as a biomarker of residual inflammation in cardiovascular patients, CRP itself has no direct role in the atherogenic process 10, 11 thus diminishing the interest in its targeting for therapeutic purposes.
Hence the need to look at data coming from laboratory research to trace back the pathogenetic cascade leading to CRP production. On this notice, a consistent amount of literature reports that IL-1b, a primordial cytokine in the inflammatory cascade, is a crucial regulator of vascular biology in the atherosclerotic process. 12 A typical characteristic of several auto-inflammatory disorders is the activation of a positive amplification loop driven by IL-1 pathway, comprising multiple secondary inflammatory mediators, as IL-6, which in turn leads to hepatic CRP production. IL-1b, the primary circulating form of IL-1, is produced as a precursor (pro-IL-1b) and cleaved following activation of the NLRP3 inflammasome by caspase-1. Active IL-1b consequently establishes the pathogenetic cascade involved in a broad spectrum of auto-inflammatory disorders, enclosing atherosclerosis.
The lack of epidemiologic studies assessing the validity of IL-1b as a biomarker of increased cardiovascular risk stands on the absence of reliable methods to directly measure active cytokine in plasma, as it possible for downstream CRP production. However, the parallel acquisition of strong experimental data, which implicated IL-1b in atherogenesis starting in the 1980s 13 and continuing up to nowadays (see also Ref. 3 for review), supported the concept that this molecular pathway was an attractive target for novel therapies. More recently, it has been shown that inflammatory monocytes engulf cholesterol crystals and trigger the NLRP3 inflammasome, 14 thus providing a pathophysiological link between two key events of the atherogenic process: cholesterol deposition and activation of systemic inflammation. Based on these clinical, epidemiological and experimental data, the large-scale CANTOS was launched in 2011 to test the inflammatory hypothesis of atherosclerosis, targeting IL-1b pathway with canakinumab in patients with stable coronary artery disease and with 'residual inflammatory risk,' defined as a persistent elevation of hsCRP above 2 mg/L.
Lessons for basic scientists
After 6 years, the results of CANTOS trial establish for the first time a proof of concept that targeting inflammatory processes in high risk patients significantly improves clinical outcomes. Besides the undoubtedly important implications for clinicians, the CANTOS results also challenge basic scientists' perspective. We are aware that despite several progresses, advances and discoveries obtained by basic cardiovascular research, filling the gap from experimental animal findings to human pathology and clinical translation is often a demanding task. What we should learn from the CANTOS trial is that only with a close collaboration between clinical, epidemiologic, and bench investigators, we can translate the progresses reached in experimental science to clinical application.
Another notable issue arising from the CANTOS trial relies on the relationship established between the culprit molecular mechanism, IL1b, and the related biomarker, hsCRP. Likely, this rationale was one of the key to success of the trial, being the former one the biological target, chosen on the basis on large experimental evidence, and the latter one a reliable downstream biomarker that allowed to appropriately select those patients who could benefit of such a therapy. This concept should encourage basic scientists in looking at their results by proposing translational tools that could help clinical trialists in striving mechanistic hypotheses for a rigorous clinical evaluation.
Not least, the CANTOS results propose IL-1 pathway as a master regulator of inflammation in vascular biology. We should not be surprised to discover further cardiovascular diseases where IL-1b plays crucial pathophysiological roles 15 and where the lessons learned from CANTOS could help in testing novel therapeutic avenues. 
